Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

4.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
3 Reasons to Sell GDRX and 1 Stock to Buy Instead
GoodRx’s stock price has taken a beating over the past six months, shedding 30.4% of its value and falling to $4.55 per share. This was partly driven by its softer quarterly results and may have... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
3 of Wall Street’s Favorite Stocks Showing Warning Signs
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Assessing GoodRx Holdings: Insights From 4 Financial Analysts
Via Benzinga
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Introduces New E-commerce Experience for Retail Pharmacies
From GoodRx
Via Business Wire
3 Small-Cap Stocks in Hot Water
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement
From GoodRx
Via Business Wire
3 Stocks Under $10 Skating on Thin Ice
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending
From GoodRx
Via Business Wire
GoodRx (GDRX) Q4 2024 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M. 
Via Benzinga
GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next... 
Via StockStory
GoodRx Reports Fourth Quarter and Full Year 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Earnings: What To Look For From GDRX
Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results tomorrow before the bell. Here’s what investors should know. 
Via StockStory
GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats
From GoodRx
Via Business Wire
1 Healthcare Stock Primed for Growth and 2 to Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
1 Healthcare Stock Primed for Growth and 2 to Snub
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer
From GoodRx
Via Business Wire
GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
Scott Wagner Joins GoodRx Board of Directors
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Offering Free Telehealth Appointments to Los Angeles Residents Affected by Wildfires
From GoodRx
Via Business Wire
GoodRx Unleashes “GoodRx for Pets,” Simplifying Access and Reducing Costs for Pet Medications
From GoodRx
Via Business Wire
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
From GoodRx
Via Business Wire
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
From GoodRx Holdings, Inc.
Via Business Wire
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.